Pharmacy Times – February 2014


Drug Interactions: Insights and Observations


Kinase Inhibitors: An Update


John R. Horn, PharmD, FCCP and Philip D. Hansten, PharmD






  1. Horn JR, Hansten PD, Drug Interactions with Tyrosine Kinase Inhibitors. Pharmacy Times. 2010;76(April):37.
  2. Hardy KD, et al. Studies on the Role of Metabolic Activation in Tyrosine Kinase Inhibitor-Dependent Hepatotoxicity: Induction of CYP3A4 Enhances the Cytotoxicity of Lapatinib in HepaRG Cells. Drug Metab Dispos. 2014;42:162-71.
  3. Teo YL, et al. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat. 2012;133:703-11